Commitments and Contingencies - Additional Information (Detail) $ in Thousands, € in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2016 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2016 EUR (€)	Dec. 31, 2015 USD ($)	Aug. 31, 2013 USD ($)	Aug. 31, 2013 EUR (€)	May 31, 2013 USD ($)
Sale Leaseback Transaction [Line Items]
Accrued in other current liabilities	$ 5,036		$ 5,036			$ 6,999
Company had royalty and license expenses relating to those agreements	300	$ 200	500	$ 400
Current portion of contingent consideration	1,143		1,143			1,286
Contingent consideration non-current portion	4,532		4,532			4,230
Change in fair value of acquisition contingencies			353
Research and development milestones [Member]
Sale Leaseback Transaction [Line Items]
Milestone payments paid	200	$ 500	900
BioHelix [Member]
Sale Leaseback Transaction [Line Items]
Payments for Royalties	0		200	$ 100
Current portion of contingent consideration	1,100		1,100
Contingent consideration non-current portion	4,200		4,200
BioHelix [Member] | Minimum [Member]
Sale Leaseback Transaction [Line Items]
Contingent consideration									$ 5,000
BioHelix [Member] | Maximum [Member]
Sale Leaseback Transaction [Line Items]
Contingent consideration									$ 10,000
Andiatec Acquisition [Member]
Sale Leaseback Transaction [Line Items]
Contingent consideration non-current portion	100		100
Andiatec Acquisition [Member] | Research and development milestones [Member]
Sale Leaseback Transaction [Line Items]
Contingent consideration	3,300		3,300		€ 3.0
Andiatec Acquisition [Member] | Maximum [Member]
Sale Leaseback Transaction [Line Items]
Contingent consideration							$ 600	€ 0.5
Claims and litigation [Member]
Sale Leaseback Transaction [Line Items]
Accrued in other current liabilities	100		100			200
Research and Development Agreements [Member]
Sale Leaseback Transaction [Line Items]
Current commitments	$ 3,600		$ 3,600			$ 4,200